Abstracts Archive - Page 2071 of 2425 - ACR Meeting Abstracts

Abstract Number: 2735 • 2013 ACR/ARHP Annual Meeting
Integrative Analysis Of Multiple Omics Technologies Reveals a Novel Therapeutic Target For Rheumatoid Arthritis (RA)
David L. Boyle¹, John Whitaker², Beatrix Bartok³, Wei Wang⁴ and Gary S. Firestein⁵, ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Chemistry, UCSD School of Medicine, La Jolla, CA, ³Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁴Chemistry, UCSD, La Jolla, CA, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Identifying novel therapeutic targets for immune-mediated disease has become increasingly challenging. We used an unbiased method to integrate multiple “omics” methodologies and evaluate…
Abstract Number: 2700 • 2013 ACR/ARHP Annual Meeting
Abnormal Mitochondrial Electron Transport Chain Activity At Complex I Is Regulated By Nitric Oxide and N-Acetylcysteine In Lupus Lymphocytes
Edward Doherty¹ and Andras Perl², ¹Immunology, SUNY Upstate, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) peripheral blood lymphocytes (PBL) show mitochondrial dysfunction, characterized by elevated mitochondrial transmembrane potential (Δψm) and mass and low ATP, attributed…
Abstract Number: 2695 • 2013 ACR/ARHP Annual Meeting
Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger
Linda Rehaume¹, Stanislas Mondot², Daniel Aguirre de Cárcer², Jared Velasco¹, Helen Benham¹, Sumaira Hasnain³, Jaclyn Bowman¹, Merja Ruutu¹, Philip Hansbro⁴, Michael McGuckin³, Mark Morrison² and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²CSIRO Livestock Industries, Brisbane, Australia, ³Mater Medical Research Institute, Brisbane, Australia, ⁴Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Chronic inflammatory diseases known as spondyloarthropathies (SpA) including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease, collectively affect 3%…
Abstract Number: 2696 • 2013 ACR/ARHP Annual Meeting
Impaired Bacterial Clearance and An Exuberant Inflammatory Response Promote Chlamydia-Induced Reactive Arthritis In SKG Mice
Athan Baillet¹, Linda Rehaume², Helen Benham², Connor O'Meara³, Charles Armitage⁴, Marina Harvie⁴, Geraldine Brizard⁵, Jared Velasco², John V. Forrester⁶, Mariapia Degli-Esposti⁵, Kenneth Beagley⁴ and Ranjeny Thomas², ¹Diamantina Institute, The University of Queensland, Brisbane, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Institute of Health & Biomedical Innovation, Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia, ⁴Institute of Health & Biomedical Innovation, Brisbane, Australia, ⁵Lions Eye Institute, Nedlands, Australia, ⁶Lions Eye Institute, Nedlands, Bahrain
Background/Purpose: The sterile inflammatory arthritis associated with spondylitis, uveitis and rash, known as reactive arthritis, commences weeks after certain gastrointestinal or genitourinary infections, including Salmonella…
Abstract Number: 2697 • 2013 ACR/ARHP Annual Meeting
Identification Of Genetic and Epigenetic Alterations In Spondyloarthritis
Tibor A. Rauch¹, Beata Tryniszewska¹, Andras Vida¹, Timea Ocsko¹, Sandor Szanto², Holly L. Rosenzweig³, Matthew A. Brown⁴, Gethin P Thomas⁵, Katalin Mikecz¹ and Tibor T. Glant¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Rheumatology, University of Debrecen, Debrecen, Hungary, ³Oregon Health & Science University, Portland, OR, ⁴Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁵Translational Reserch Institute, University of Queensland Diamantina Institute, Woolloongabba, Australia
Background/Purpose: Ankylosing spondylitis (AS) is the prototypic spondyloarthritis and affects approximately 0.2-0.5% of the human population. It is estimated that genetic risk factors contribute >90%…
Abstract Number: 2698 • 2013 ACR/ARHP Annual Meeting
The Treg/Th17 Imbalance Of Patients With Systemic Lupus Erythematosus Were Mediated By Mir-663 Through Down-Regulating TGF-β1 Secretion Of Bone Marrow-Derived Mesenchymal Stem Cells
Lingyu Geng¹, Xia Li¹, Xuebing Feng² and Lingyun Sun³, ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Systemic lupus erythematosus (SLE) patients exist an imbalance between CD4+CD25+FoxP3+ T regulatory (Treg) and IL-17-producing cells (Th17). Correction of this Treg/Th17 imbalance may have…
Abstract Number: 2699 • 2013 ACR/ARHP Annual Meeting
Transcription Factor RFX1 Regulates Th17 Differentiation and Its Role In The Pathogenesis Of Systemic Lupus Erythematosus
Ming Zhao¹, Gongping Liang¹, Qian Tang², Yang Yang¹, Yixin Tan¹ and Qianjin Lu¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Recently, evidence is emerging that abnormal regulation of Th17 differentiation plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). However, the…
Abstract Number: 2701 • 2013 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling
Alexandros P. Grammatikos¹, Debjani Ghosh² and Vasileios C. Kyttaris¹, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Microbiology and Immunology, The Brody School of Medicine, East Carolina University, Greenville, NC
Background/Purpose: Systemic Lupus Erythematosus (SLE) T cells display an aberrant response to CD3/ TCR stimulation. The CD3/TCR complex in SLE is characterized by the substitution…
Abstract Number: 2702 • 2013 ACR/ARHP Annual Meeting
Molecular Pathogenesis and Genetics Of Tartrate-Resistant Acid Phosphatase Deficiency In Systemic Lupus Erythematosus
Jie An¹, Tracy A. Briggs², Audrey Dumax-vorzet², Alice Wiedeman³, Laurence Chaperot⁴, Joel Plumas⁴, Yanick J. Crow² and Keith B. Elkon⁵, ¹Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, ²Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ³Department of Immunology, University of Washington, Seattle, WA, ⁴Inserm U823/Ujf/EFS, Immunobiology & Immunotherapy of Cancers, La Tronche, France, ⁵Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Biallelic mutations in ACP5, encodng tartrate-resistant acid phosphatase (TRAP), result in the immuno-osseous disorder spondyloenchondrodysplasia (SPENCD), characterized by a variety of autoimmune phenotypes –…
Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting
An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression
Jian Zhao¹, Brendan M. Giles², Rhonda L. Taylor³, Gabriel A. Yette², Kara M. Lough², Lawrence J. Abraham³, Hui Wu⁴, Patrick M. Gaffney⁵, Jennifer A. Kelly⁶, Kenneth M. Kaufman^7,8, John B. Harley^9,10, Carl D. Langefeld¹¹, Elizabeth E. Brown¹², Jeffrey C. Edberg¹³, Robert P. Kimberly¹⁴, Daniela Ulgiati³, Betty P. Tsao¹ and Susan A. Boackle¹⁵, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Western Australia, Perth, Western Australia, Australia, ⁴Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…
Abstract Number: 2704 • 2013 ACR/ARHP Annual Meeting
Twist1 Regulates Transforming Growth Factor Beta Dependent Activation Of Fibroblasts In Fibrosis
Katrin Palumbo-Zerr¹, Andrea Liebl¹, Pawel Zerr¹, Michal Tomcik², Alfiya Distler¹, Christian Beyer¹, Oliver Distler³, Georg Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Twist1 is a member of the tissue-restricted class B of basic-helix-loop-helix (bHLH) transcription factors acting as master regulators on different tissues. Twist1 is controlled…
Abstract Number: 2705 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Microrna-155 Ameliorated Experimental Fibrosis By Suppressing Wnt and Akt Pathways
Qingran Yan¹, Qiong Fu¹, Jie Chen¹, Xinfang Huang¹, Nan Shen^2,3 and Chunde Bao¹, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ³Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: MicroRNA-155 plays a critical role in various physiological and pathological processes including cell proliferation and migration, epithelial- mesenchymal transition, as well as inflammation. Previous…
Abstract Number: 2706 • 2013 ACR/ARHP Annual Meeting
Fli1 Haploinsufficiency Exacerbates Dermal Fibrosis Via Activation Of Fibroblasts, Endothelial Cells and Macrophages In Bleomycin-Treated Mice
Takashi Taniguchi¹, Yoshihide Asano¹, Kaname Akamata¹, Shinji Noda¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Maria Trojanowska² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disorder with clinical manifestations resulting from immune activation, vascular injuries and fibrosis development. Previous reports suggest that…
Abstract Number: 2707 • 2013 ACR/ARHP Annual Meeting
Downregulation Of KLF5 and Fli1 Cooperatively Contribute To Distinct Manifestations Of Systemic Sclerosis In Vitro and In Vivo
Shinji Noda¹, Yoshihide Asano¹, Katsuhito Fujiu², Ichiro Manabe², Ryozo Nagai², Kaname Akamata¹, Takashi Taniguchi¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Daisuke Tsuruta³, Maria Trojanowska⁴ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although the…
Abstract Number: 2708 • 2013 ACR/ARHP Annual Meeting
The Hedgehog Transcription Factor Gli-2 Is a Novel Downstream Mediator Of The Pro-Fibrotic Effects Of Transforming Growth Factor-Beta
Barbora Sumova^1,2, Cinzia Cordazzo³, Katrin Palumbo-Zerr⁴, Clara Dees⁴, Pawel Zerr⁴, Oliver Distler⁵, Georg Schett⁶, Ladislav Senolt⁷ and Joerg H. W. Distler⁴, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, ²Department of Rheumatology of the First Faculty of Medicine, Institute of Rheumatology and Connective Tissue Research Laboratory, Prague, Czech Republic, ³3Dipartimento Cardiotoracico e Vascolare, Laboratory of Respiratory Cell Biology, University of Pisa, Pisa, Italy, ⁴Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by aberrant activation of fibroblasts with increased release of extracellular matrix components. TGFβ is a key-mediator of fibroblast activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].